Florida Cancer Specialists

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer4 trials
• Lung cancer2 trials
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 34 trials
• Phase 23 trials
• Phase 1/21 trial

Status

• Active, not recruiting4 trials
• Completed3 trials
• Recruiting1 trial

Lead sponsor

• Pfizer7 trials
• Seagen, a wholly owned subsidiary of Pfizer1 trial

Running trials

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

  NCT06966453· Phase 1/2· Pfizer· Source

• Active, not recruiting

  A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

  NCT05654623· Phase 3· Pfizer· Source

• Active, not recruiting

  Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

  NCT03395197· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

  NCT03052608· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting

Closed trials

• Completed

  A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

  NCT04539938· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Completed

  Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

  NCT02007512· Phase 2· Pfizer· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

  NCT01889238· Phase 2· Pfizer· Source